High-Performance Science Teams™ helps life science product teams R&D, product management, QC, regulatory, operations, marketing, and technical support launch reagents, assay kits, and consumables on time and on spec. It targets the cross-functional behaviors behind spec creep, late lot-release criteria, and launches the commercial team isn’t ready to support.
How often do new life science products actually deliver?
Less often than roadmaps assume. In TechLink’s 2024 R&D Innovation Performance Study of R&D-driven companies, about three-quarters of respondents reported that half or fewer of their new product development projects result in sales, more than half said half or fewer hit projected sales targets, and about a quarter take more than a year to develop a new product. Meanwhile, 83% plan to increase their number of SKUs over the next three years.
The study spans industries life science is a minority of respondents so treat these as directional. But for a reagent or kit company adding SKUs every quarter, the implication is uncomfortable: more launches through the same cross-functional machinery means more of the same slippage.
Where do reagent and kit launches break down?
Spec creep in R&D. The assay team keeps optimizing sensitivity or dynamic range after the product requirements were set, because no one has the authority or the protocol to freeze the design.
Product managers with accountability but no authority. Product management owns the launch date but can’t make R&D, QC, or supply chain commit to theirs.
Lot-release criteria set late. QC specifications and stability data arrive after design transfer, and lot-to-lot consistency complaints arrive after launch.
Design controls treated as regulatory’s problem. For products moving from RUO toward IVD or ISO 13485 environments, documentation is back-filled instead of built into how the team works.
Claims the data doesn’t yet support. Marketing launches on application notes and validation data that R&D considers preliminary.
Technical support and FAS learn about the product at launch. The people customers call first are the last to be trained.
Why doesn’t a new stage-gate process or PLM system fix it?
When launches slip, tools companies reach for vertical fixes: a formal stage-gate process, a PLM or QMS platform, a reorganization that moves product management under a different executive. In the same TechLink study, only 40% of companies reported extensively using a gating process so formal process is a real gap for many.
But a gate only works if the team at the gate is willing to make the call. A PLM system documents the bill of materials; it doesn’t resolve the argument between R&D and product management about whether the kit is ready. That argument is a team behavior, and it needs a team-level fix.
How does High-Performance Science Teams™ work for product teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to the intact new product introduction team, working on real launches in your pipeline.
Launch pattern
Root behavior
What HPT installs
Spec creep and slipped design freeze
No agreed decision rule for “good enough”
A decision protocol tied to product requirements, with a named decision owner and date
PM accountability without authority
Functional goals outrank launch goals
Shared launch goals and cross-functional commitments each function signs
Late QC and stability criteria
QC brought in at design transfer
QC, regulatory, and operations seated in the core team from feasibility onward
Marketing–R&D claims conflict
Disagreement handled by escalation
A conflict protocol that settles claims against the validation data, in the room
Unready tech support and FAS
Commercial handoff treated as an event
Peer accountability for launch readiness across R&D, marketing, and support
How does this connect to commercial readiness?
High-Performance Science Teams™ aligns the team that builds the product. Bench to Business™, our companion program, builds the customer-facing skills of the Field Application Scientists and technical specialists who support it. Many product companies run both: one for the launch team, one for the people carrying the product to customers.
Who is it for?
VPs of Product Management and R&D, CCOs, product marketing leaders, and QC, QA, and operations heads at life science tools, reagent, antibody, assay kit, and consumables companies — typically in the $10M–$500M revenue range and launching multiple products a year.
How do we get started?
Start with the Science Team 360™, a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your product development team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
Why do life science product launches slip?
Most slips trace to cross-functional behavior rather than technical failure: design specs that never freeze, product managers without authority over other functions, QC and regulatory brought in late, and commercial teams trained after launch.
What is a high-performance product development team?
It is a cross-functional team -R&D, product management, QC, regulatory, operations, marketing, and support, that shares one set of launch goals, has explicit decision rights, resolves conflicts openly, and holds each other accountable for launch readiness.
Does High-Performance Science Teams™ replace a stage-gate process?
No. It makes gates work by ensuring the team at each gate makes a clear decision on agreed criteria instead of deferring it.
Is this relevant for RUO-to-IVD transitions?
Yes. Teams moving toward design-controlled environments benefit from building cross-functional documentation and decision habits early, rather than back-filling them.
How do we start?
With the Science Team 360™, a confidential team diagnostic that shows where alignment, decision rights, and accountability break down in your launch team.
Sources
TechLink, 2024 R&D Innovation Performance Study — Executive Summary (conducted by The MPI Group; n=152 U.S. executives, cross-industry).
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
High-Performance Science Teams™ helps internal manufacturing and technical operations teams at therapeutics companies process and analytical development, manufacturing, MSAT, QC, QA, supply chain, and external manufacturing, operate as one team from clinical supply to commercial launch. It targets the behaviors behind late CMC surprises, inspection-readiness gaps, and CDMO relationships that drift, the issues that increasingly decide approval timelines.
Why is manufacturing now the critical path to approval?
For most of a program’s life, CMC runs in the background. Then the pivotal readout lands, the BLA or NDA timeline locks, and technical operations becomes the critical path overnight — process performance qualification, comparability, commercial-scale validation, and pre-approval inspection readiness all at once.
FDA’s own letters show how often that goes wrong. A peer-reviewed Johns Hopkins analysis of complete response letters for 43 novel therapeutics that were ultimately approved between 2020 and 2024 found manufacturing deficiencies were the most common problem: 65% of letters cited facility issues and 51% cited CMC issues, more than efficacy or safety. The median time from CRL to eventual approval was 1.28 years (Dilek et al., Therapeutic Innovation & Regulatory Science, 2026).
Facility findings and CMC gaps are technical on paper. In practice, many start as team problems: data that didn’t move between functions, risks that surfaced late, and decisions no one clearly owned.
What does team dysfunction look like in biotech technical operations?
R&D culture meets GMP reality. Teams that grew up in discovery treat documentation, change control, and deviations as paperwork — until a mock inspection shows otherwise.
Process development versus manufacturing. PD optimizes the process; manufacturing inherits it at scale. Comparability and scale-up questions surface during engineering runs instead of in design.
Quality as the gate at the end. QA and QC review what operations already decided, so issues are found at batch disposition or in the CMC module draft, not when they were cheap to fix.
CMC timelines that don’t match clinical timelines. Clinical development plans the readout; technical operations learns the filing date secondhand and compresses PPQ to fit.
External manufacturing drift. In hybrid models, the CDMO relationship is owned by one person. Tech transfer, person-in-plant oversight, and quality agreements live in silos, and the sponsor hears about problems late.
Hiring faster than norms can form. A new facility or launch ramp doubles headcount, and decision rights, escalation paths, and handoffs never get written down.
Why don’t new systems, consultants, or a bigger team fix it?
Therapeutics companies reach for vertical fixes when CMC gets tight: a new QMS or LIMS, an inspection-readiness consultant, a reorganization under a new Chief Technical Officer, more headcount. Each has its place. A mock inspection finds the gaps; it doesn’t change how process development, manufacturing, and QA work together to close them.
The pattern behind most CMC surprises is horizontal information and accountability that don’t cross functional lines and it needs a horizontal fix.
How does High-Performance Science Teams™ work for manufacturing teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to technical operations leadership and cross-functional CMC teams, working on live programs, live filings, and live CDMO relationships.
CMC-risk pattern
Root behavior
What HPT installs
Late comparability and scale-up surprises
PD and manufacturing goals misaligned
Joint PD–MSAT–manufacturing ownership of scale-up and transfer readiness
Issues found at QA review
Quality brought in after decisions
QA and QC seated in program decisions early, with an explicit protocol for disagreement
Compressed PPQ and filing timelines
CMC and clinical plans built separately
A shared integrated timeline with named decision owners across clinical, regulatory, and technical operations
CDMO problems discovered late
One-person ownership of external partners
Cross-functional external-manufacturing team with early-warning norms and shared accountability
Inspection-readiness gaps
GMP habits not yet team norms
Peer accountability for documentation, deviation, and change-control discipline
How does this fit with inspection readiness and quality systems?
High-Performance Science Teams™ does not replace your QMS, regulatory CMC strategy, or mock-inspection program. It changes how the people using them share information, raise risk, and make decisions, which is what inspectors see when they interview your team.
Who is it for?
Chief Technical Officers, SVPs and VPs of Technical Operations, Manufacturing, CMC, Quality, and Supply Chain, site heads, and CEOs and CHROs at clinical- and commercial-stage biotech and therapeutics companies especially those preparing a BLA or NDA, bringing an in-house GMP facility online, moving from clinical to commercial supply, or managing a hybrid in-house and CDMO network.
How do we get started?
Start with the Science Team 360™, a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your technical operations team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
Why do manufacturing issues delay FDA approval?
In a Johns Hopkins analysis of complete response letters for novel therapeutics ultimately approved in 2020–2024, facility deficiencies appeared in 65% of letters and CMC deficiencies in 51%, more often than efficacy or safety issues. Many trace to late-surfacing risks, unclear ownership, and gaps between development, manufacturing, and quality.
What is CMC readiness?
CMC readiness means chemistry, manufacturing, and controls data, validated processes, and GMP facilities are ready to support a regulatory filing and pre-approval inspection. It depends on process development, manufacturing, MSAT, QC, QA, regulatory, and supply chain working from one plan.
How can a biotech manufacturing team prepare for a pre-approval inspection?
Beyond mock inspections and document reviews, teams prepare by aligning functions on one integrated timeline, clarifying who owns each decision, bringing QA in early, and building consistent GMP habits so every team member tells the same accurate story.
Does High-Performance Science Teams™ help manage CDMO partners?
Yes. It builds a cross-functional external-manufacturing team with shared accountability and early-warning norms, so CDMO issues surface early instead of at batch release or in an inspection.
How do we start?
With the Science Team 360™, a confidential diagnostic that shows where alignment, decision rights, and accountability break down in your technical operations team.
Sources
Dilek S., Woods R.H., Ballreich J., Moore T.J., Alexander G.C. “Deficiencies Delaying Prescription Drug Approvals by the U.S. Food and Drug Administration, 2020–2024.” Therapeutic Innovation & Regulatory Science 60(3):837–846 (2026) — https://doi.org/10.1007/s43441-026-00921-3
Pharma Manufacturing, “FDA’s CRLs reveal 74% of applications rejected for quality, manufacturing issues” (July 2025; analysis of 202 CRLs, 2020–2024) — https://www.pharmamanufacturing.com/all-articles/article/55302937/fdas-crls-reveal-74-of-applications-rejected-for-quality-manufacturing-issues
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
High-Performance Science Teams™ is a team-level behavioral program from Bench to Business™ and Guttman Development Strategies for therapeutic R&D teams. It addresses the non-scientific reasons discovery programs stall deferred go/no-go decisions, biology–chemistry–DMPK silos, and disagreement that surfaces after the project meeting instead of in it by installing explicit decision rights, conflict protocols, and peer accountability.
Why do drug discovery programs stall when the science is sound?
Every head of research has lived some version of this. The target is validated, the assay cascade works, the chemistry is tractable and the program still drifts. Lead optimization runs two quarters past plan. Candidate nomination slips. The go/no-go meeting ends with the most expensive sentence in drug discovery: “Let’s generate one more dataset.”
In our experience, the root cause is rarely a failed experiment. It is how the project team makes and avoids making decisions. Scientific rigor is not the constraint. Team behavior is.
Broader R&D data points the same way. In TechLink’s 2024 R&D Innovation Performance Study of 152 U.S. executives at R&D-driven companies, 21% named lack of leadership commitment and 16% named poor collaboration across the company as barriers to innovation, and only 46% said they extensively use cross-functional work to develop new products. The study is cross-industry rather than life-science specific, but the pattern will look familiar to anyone who has sat in a program review.
What does team dysfunction look like inside a therapeutic research program?
Go/no-go drift. Kill decisions get deferred because no one clearly owns the call. Marginal programs keep consuming FTEs, CRO budget, and animal studies that the next target needs.
Functional silos across biology, medicinal chemistry, DMPK, and safety. Each function optimizes its own milestone. SAR decisions are made without ADME or tox input until the liabilities show up late.
The PI model of leadership. Project leaders trained as principal investigators default to owning every decision. Team members defer instead of challenging the hypothesis.
The meeting after the meeting. Real disagreement about target biology, biomarker strategy, or the target product profile happens in hallways and side channels not in the project team meeting where it could be resolved.
Translational handoff friction. Discovery hands a development candidate to CMC, clinical, and regulatory without shared criteria, and IND-enabling work turns into rework.
Why don’t reorganizations, new software, or consultants fix it?
When R&D productivity stalls, life science companies reach for vertical fixes: redraw the org chart, add a portfolio management platform, bring in a strategy firm. Each can help. None changes how the people around the table decide, disagree, and hold each other accountable.
A reorganization moves the boxes; the same behaviors move with them. An ELN or portfolio tool records decisions; it doesn’t make them. And a consultant’s recommendation still has to be executed by the same team whose dynamics produced the problem. We say that as consultants. It is a horizontal problem, and it needs a horizontal fix.
How does High-Performance Science Teams™ work for R&D teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model — refined over more than three decades with leadership teams at organizations including Johnson & Johnson, Novartis, and Mars — to scientific teams. We work with the intact project or leadership team on its real programs, not with individuals in a classroom.
Stall pattern
Root behavior
What HPT installs
Deferred go/no-go decisions
Unclear decision rights
A written decision protocol: who decides, on what criteria, by when — and decisions made in the room
Chemistry, biology, and DMPK silos
Functional goals outrank program goals
Shared program-level goals and a target candidate profile every function signs up to
Leader-centric decisions
Hub-and-spoke leadership
Leader as coach; team members accountable to each other, not only to the leader
Hidden scientific disagreement
No conflict protocol
Depersonalized conflict: issues raised as business issues, in the meeting, with data
Late translational rework
Handoffs not co-owned
Accountability agreements between discovery, development, CMC, and clinical
What changes when a discovery team operates horizontally?
These are the outcomes teams target and track through the engagement measured against their own Science Team 360™ baseline rather than a generic benchmark:
Faster, cleaner kill decisions, so resources move to the programs with the strongest data.
Candidate nomination packages built against a shared target candidate profile from the start of lead optimization.
Fewer late surprises in DMPK, safety, and CMC because those voices are in the decision early.
Stronger retention of senior scientists, who stay where their judgment is heard and acted on.
Who is High-Performance Science Teams™ for?
CSOs, Heads of R&D, VPs of Discovery and Translational Science, and program leaders at emerging and mid-size biotechs and research organizations running multiple programs through discovery and IND-enabling stages. It is designed for intact teams — a program team, a discovery leadership team, or a cross-functional portfolio committee.
How do we get started?
Start with the Science Team 360™ a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your R&D organization. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
What is a high-performance team in drug discovery?
A high-performance drug discovery team is a cross-functional project team — biology, chemistry, DMPK, safety, and translational — that shares one set of program goals, has explicit decision rights, resolves scientific disagreement openly in the meeting, and holds itself accountable for milestones rather than relying on the project leader to do it.
How is High-Performance Science Teams™ different from leadership training?
Leadership training develops individuals in a classroom. High-Performance Science Teams™ works with an intact team on its live programs and decisions, changing how the team operates together.
Does it replace stage-gate or portfolio governance?
No. Stage gates define when decisions should happen. High-Performance Science Teams™ makes sure the team actually makes them — on time, on agreed criteria, and with every function’s input.
Who delivers the program?
High-Performance Science Teams™ is delivered by Bench to Business™ in partnership with Guttman Development Strategies, whose horizontal high-performance team methodology anchors the program.
How is progress measured?
Teams complete the Science Team 360™ at baseline and again later in the engagement, and track operating measures they choose — such as decision cycle time and milestone slippage.
Sources
TechLink, 2024 R&D Innovation Performance Study — Executive Summary (conducted by The MPI Group; n=152 U.S. executives, cross-industry).
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
High-Performance Science Teams™ helps CDMO site and program teams, process development, MSAT, manufacturing, QA, QC, and client program management, work as one team across the handoffs where biomanufacturing programs slip. It targets the behaviors behind rocky tech transfers, repeat deviations closed as “human error,” and clients who hear different answers from different functions.
Why do CDMO programs slip when the process is sound?
Ask a CDMO site head where a program went sideways, and the answer is rarely the bioreactor. It’s the handoff: process development transferring a package MSAT didn’t help write, manufacturing receiving a batch record that doesn’t match, QA discovering a gap during review instead of during design, and the client program manager relaying a schedule change no one agreed on internally.
Each function is usually competent in isolation. The failure happens between them, and in a contract manufacturing business, the client experiences every internal seam.
What does team dysfunction look like on a CDMO site?
Tech transfer over the wall. Process development hands over a package; MSAT inherits unanswered scale-up questions; the engineering run becomes the discovery phase.
QA versus operations. Quality is experienced as the department that says no, so operations routes around it until review — and batch disposition slows down.
Deviations closed as “human error.” “Human error” remains one of the most commonly cited deviation root causes, and quality leaders increasingly argue it often masks deeper system and communication problems. Retraining is assigned; the underlying handoff stays broken.
Change control bottlenecks. Every function has a veto and no one owns the decision timeline.
Shift and handover gaps. Critical context lives in individuals, not in team agreements.
Many voices to the client. The program manager, site head, and QA lead give the client different versions of the same schedule or investigation status.
Why don’t MES, reorganizations, or more training fix it?
CDMOs reach for vertical fixes: a new MES or electronic batch record system, a reorganized MSAT function, another round of GMP retraining. These are often necessary. But an electronic batch record digitizes the handoff; it doesn’t make process development and manufacturing agree on it. Retraining addresses the individual; the deviation came from the system between individuals.
It is a horizontal problem, performance across functions, and it needs a horizontal fix.
How does High-Performance Science Teams™ work for biomanufacturing teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to site leadership teams and client program teams, working on live programs, live investigations, and live client commitments.
Site pattern
Root behavior
What HPT installs
Rocky tech transfer and engineering runs
Handoffs owned by the sender, not both sides
Joint PD–MSAT–manufacturing accountability for transfer readiness
QA–operations friction
Quality seen as a gate, not a teammate
QA seated in program decisions early, with an explicit protocol for disagreement
Repeat “human error” deviations
Investigations stop at the individual
Team norms for surfacing system and handoff causes during CAPA
Change control delays
Vetoes without decision ownership
A decision charter with named owners and timelines
Inconsistent client messages
No single internal position
Align-before-you-speak protocol so the client hears one answer
How does this fit a CDMO’s commercial motion?
CDMOs win repeat business on reliability, and reliability is a team behavior. Many CDMOs pair two motions: High-Performance Science Teams™ for site, technical, and quality teams, and Bench to Business™ for the BD leads, program managers, and technical account managers who carry the client relationship.
Who is it for?
Site heads, VPs of Operations, Heads of Quality, MSAT and process development leaders, program management leaders, and CHROs at biologics, cell and gene therapy, viral vector, and small-molecule CDMOs — especially sites scaling headcount quickly or onboarding new client programs.
How do we get started?
Start with the Science Team 360™ a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your site or program team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
What causes delays in CDMO tech transfer?
Beyond technical scale-up issues, tech transfer delays usually come from handoffs owned by one side: process development packages written without MSAT and manufacturing input, late QA involvement, and unclear decision ownership for changes.
How can a CDMO improve right-first-time performance?
By treating right-first-time as a cross-functional outcome: aligning PD, MSAT, manufacturing, and QA on shared goals, clarifying decision rights, and investigating deviations for system and handoff causes rather than stopping at individual error.
Does High-Performance Science Teams™ replace quality systems or GMP training?
No. It works alongside your QMS and training programs, improving how teams collaborate, escalate, and investigate within them.
How does team performance affect the CDMO client experience?
Clients experience every internal seam. Teams that align before communicating give the client one consistent answer on schedules, investigations, and risks — which builds the trust behind repeat business.
How do we start?
With the Science Team 360™, a confidential diagnostic of your site or program team that pinpoints where alignment and accountability break down.
Sources
GEN — Genetic Engineering & Biotechnology News, “Blaming Just Human Error Can Mask Deeper Bioprocess Problems” — https://www.genengnews.com/topics/bioprocessing/biopharma-must-do-more-to-understand-deviations/
BioProcess Online, “‘Human Error’ Deviations: Why You Should Stop Creating (Most Of) Them” — https://www.bioprocessonline.com/doc/human-error-deviations-why-you-should-stop-creating-most-of-them-0001
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
High-Performance Science Teams™ helps sponsor-side clinical study teams clinical operations, medical, data management, biostatistics, regulatory, and CRO partners make faster, cleaner decisions. It targets the team behaviors behind avoidable protocol amendments, slow escalations, and sponsor CRO friction, the delays a study team can actually control.
What does a day of clinical trial delay really cost?
Tufts Center for the Study of Drug Development estimates the mean direct cost of running a Phase II or Phase III trial at roughly $40,000 per day, about $23,700 per day for Phase II and $55,700 for Phase III (Tufts CSDD, 2024). That is before counting the commercial value of a later approval.
Protocol amendments are one of the most visible sources of that delay. In Tufts CSDD’s 2016 benchmark, 57% of protocols had at least one substantial amendment, nearly half of those amendments were judged avoidable, and the median direct cost to implement one was $141,000 in Phase II and $535,000 in Phase III. Tufts’ more recent benchmarking found that most amendments are now judged unavoidable driven by regulatory requests and changes in study strategy, but that still leaves a costly avoidable share, and strategy changes are often a symptom of misalignment upstream.
Which clinical trial delays are team problems, not science problems?
Enrollment curves and regulatory feedback get the blame. But inside most study execution teams, a set of controllable behaviors quietly adds weeks:
Protocols designed without operational voice. Clinical science finalizes the protocol before clinical operations, data management, and sites weigh in on feasibility, then amends it after first patient in.
Decisions escalated instead of made. The study team treats governance committees as the default decision-maker, so routine calls on eligibility clarifications or vendor issues wait for the next meeting cycle.
Medical vs. operations tension. Medical monitors and clinical operations optimize for different risks and rarely resolve the trade-off explicitly.
The sponsor–CRO blame loop. Vendor oversight becomes policing. The CRO learns to report green until it’s red, and the sponsor learns to distrust the dashboard.
Status meetings instead of decision meetings. Study team meetings recite enrollment numbers and open queries without assigning owners to the enrollment rescue plan or the database-lock critical path.
Why don’t better CTMS dashboards or another CRO fix it?
Life science companies reach for vertical fixes when a trial slips: a new CTMS or RBQM platform, a reorganized clinical operations function, a CRO switch. The dashboard shows the delay more clearly. It does not change how the study team decides what to do about it.
Switching CROs is the most expensive version of the same mistake. If the sponsor-side team’s decision rights, escalation norms, and accountability are unclear, the new partner inherits the same dynamics — along with a transition that costs months.
How does High-Performance Science Teams™ work for clinical study teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to the study execution team, working on live studies rather than simulations. Where it helps, the engagement can be designed to include CRO counterparts so the partnership operates as one team.
Delay pattern
Root behavior
What HPT installs
Avoidable protocol amendments
Feasibility input arrives after protocol finalization
Cross-functional protocol-design protocol: clinical ops, data management, biostatistics, and site input before sign-off
Slow escalations
Unclear decision rights at study-team level
A decision charter defining what the study team decides, what it escalates, and within what time frame
Medical vs. operations standoffs
Trade-offs left implicit
Explicit conflict protocol that frames disagreements as study-risk decisions
Sponsor–CRO mistrust
Oversight as policing
Joint team agreements on early bad-news reporting and shared accountability for milestones
Missed database lock
No single owner of the critical path
Peer accountability for FPI, LPI, and database-lock milestones across functions
What is outside the scope of the program?
High-Performance Science Teams™ does not replace patient-recruitment strategy, site-selection analytics, or protocol-design expertise. It makes the team that uses those inputs faster and more aligned, and it works alongside the specialist partners you already rely on.
Who is it for?
VPs of Clinical Operations, Heads of Clinical Development, CMOs, study and program leads, and alliance managers at biotech and pharma sponsors running Phase I–III programs, especially teams managing one or more CRO partnerships.
How do we get started?
Start with the Science Team 360™, a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your clinical study team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
What causes clinical trial delays that a study team can control?
Controllable delays usually come from team behavior: protocols finalized without operational and site input, decisions escalated instead of made at study-team level, unresolved medical-versus-operations trade-offs, and sponsor CRO relationships where bad news travels late.
How much does a day of clinical trial delay cost?
Tufts CSDD estimates the mean direct cost at roughly $40,000 per day for Phase II and III trials — about $23,700 for Phase II and $55,700 for Phase III — excluding lost commercial value.
How does High-Performance Science Teams™ improve sponsor–CRO collaboration?
It creates joint agreements on decision rights, early reporting of risk, and shared milestone accountability, so the sponsor and CRO operate as one study team instead of a buyer and a vendor.
Does this replace risk-based quality management or CTMS tools?
No. RBQM and CTMS surface risks and status. High-Performance Science Teams™ improves how the study team acts on that information.
How do we start?
With the Science Team 360™, a confidential team diagnostic that pinpoints where decision rights, alignment, and accountability break down before any larger engagement.
Sources
Tufts CSDD, “How Much Does a Day of Delay in a Clinical Trial Really Cost?” White paper, August 2024 — https://csdd.tufts.edu/publications/articles
Getz K.A. et al. “The Impact of Protocol Amendments on Clinical Trial Performance and Cost.” Therapeutic Innovation & Regulatory Science, 2016 — https://pubmed.ncbi.nlm.nih.gov/30227022/
Tufts CSDD, “New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance” (preprint) — https://www.researchsquare.com/article/rs-3168679/v1
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
By Stephen Manobianco, Managing Director, PSG Life Sciences | Last updated: September 25, 2026
QUICK ANSWERNew Harvard Business Review Analytic Services research shows most B2B companies have a go-to-market execution problem, not a strategy problem -and in life sciences, that gap usually lives with the PhD scientists and technical specialists who carry the customer conversation and with sales, marketing, and technical teams that aren’t operating as one unit. Closing it takes structured commercial coaching for scientists, a high-performance team alignment process, and a CRM that gives everyone the same view of the buyer.
In September 2025, Harvard Business Review Analytic Services surveyed 522 people involved in B2B sales decisions (the report, Aligning Go-to-Market Execution with Strategy to Better Address Complex Buyer Journeys, was sponsored by LeanData). The respondent pool is cross-industry -technology, manufacturing, consulting, financial services -not life sciences specifically. But I’ve spent 25+ years selling into research markets, and every pattern in this report shows up in life science commercial teams, usually in a more acute form.
Here’s what the data says, and what it means if your customer-facing team is built on PhD scientists.
What does the HBR research say about B2B go-to-market execution?
DIRECT ANSWER: The HBR research finds that 83% of B2B organizations call their go-to-market strategy very important, but only 38% describe it as very effective and only 32% say their sales, marketing, and other teams are very aligned in executing it.
The headline numbers from the survey:
83% say their GTM strategy is very important for selling to B2B buyers; only 38% say it’s very effective.
92% agree GTM strategy should align with the buyer journey -but only 29% say their organization understands today’s buyer journey very well.
78% say they need better coordination across the GTM systems used by marketing and sales.
Only 32% say their sales, marketing, and other GTM teams are very aligned.
A Bain & Co. partner interviewed for the report makes the point every CEO needs to hear: when execution isn’t set up properly, adding budget or headcount doesn’t move outcomes. In other words, hiring another rep into a broken system just gives you a more expensive broken system.
Why does the strategy-to-execution gap hit life science companies harder?
DIRECT ANSWERLife science companies feel the execution gap more because their customer-facing roles are usually filled by PhD scientists and technical specialists who were hired for scientific depth, not commercial skill, and because they sell to buying groups of PIs, lab managers, core directors, and procurement that each weigh different criteria.
The HBR report calls out buying groups as a central complication: more stakeholders, each shaped by different touchpoints before a vendor ever gets a meeting. In the survey, 34% report difficulty engaging all members of a buying group, and 31% cite a lack of knowledge of the individual buyer roles involved in the decision.
In life sciences, that buying group is the PI who cares about data, the postdoc who runs the protocol, the lab manager who owns the budget, and the procurement team that owns the vendor list. A scientist-turned-seller will instinctively talk to the person who shares their vocabulary. That’s the PI or the postdoc. The deal often stalls somewhere else.
What separates go-to-market “leaders” from “laggards” in the HBR data?
DIRECT ANSWER: GTM leaders in the HBR research are distinguished less by strategy than by execution discipline -they are far more aligned across teams, more likely to train their sales people, more likely to share common metrics, and far more likely to understand how their buyers actually buy.
HBR segmented respondents into leaders (36%), followers (42%), and laggards (22%). The gaps are striking:
Execution factor
Leaders
Laggards
Sales/marketing/other teams very aligned
63%
11%
Understand today’s buyer journey very well
53%
11%
Prioritize improving collaboration across teams
81%
49%
Training sales teams to improve effectiveness
58%
42%
Aligning on a shared GTM strategy
51%
30%
Cross-training sales and marketing on each other’s roles
36%
13%
Revenue growth achieved from better buyer-journey understanding
64%
37%
Source: Harvard Business Review Analytic Services survey, September 2025 (n=522).
Read that table as a commercial leader and two things jump out. First, alignment is the single biggest separator -63% vs. 11%. Second, the leaders invest in people: training, cross-training, role clarity. That’s not a technology story. That’s a coaching and team-operating-model story.
How do you prepare PhD scientists to execute a go-to-market strategy?
DIRECT ANSWERPrepare PhD scientists for commercial roles with structured, life-science-specific coaching applied to their live accounts -covering discovery, buying-group mapping, account planning, and CRM discipline -with their manager involved so the new behaviors stick.
The HBR survey’s top execution challenges read like a job description for a newly promoted Field Application Scientist:
A lack of feedback from buyers to improve approaches (39%)
Insufficient time to customize approaches for different customers (39%)
Reaction time too slow to act on customer and prospect signals (38%)
None of these are knowledge problems. Your PhDs know the science cold. They’re skill and habit problems: asking discovery questions instead of presenting data, qualifying the buying group instead of the friendliest scientist, logging the signal in the CRM instead of in their head. At GENEWIZ, where we scaled revenue from $17M to over $100M, the scientists who became top performers weren’t the ones with the best publication record. They were the ones who learned to run a disciplined commercial conversation.
The report also notes that among companies using AI in GTM, 45% use it to coach sales reps. A B2B sales consultant quoted in the report puts it bluntly: “I don’t want my sales reps practicing on buyers.” Neither do we. Scientists should rehearse on real account scenarios with a coach, not burn a key lab relationship learning how to handle a pricing objection.
That’s the design behind Bench to Business, PSG’s 12-week coaching program for PhD scientists, Field Application Specialists, technical sales teams, and business development professionals in customer-facing life science roles. It uses real accounts rather than generic role plays, brings managers in at kickoff, midpoint, and capstone, and ties coaching directly to discovery, stakeholder mapping, account planning, and CRM execution.
Promoted a great scientist into a customer-facing role -and the pipeline hasn’t followed? Bench to Business is a 12-week, life-science-specific coaching program led by Steve Manobianco that turns scientific expertise into commercial execution, applied to your team’s live accounts. Explore Bench to Business Coaching →
How do sales, marketing, and technical teams become a high-performance team?
DIRECT ANSWER: Sales, marketing, and technical teams become a high-performance team by agreeing on shared goals and metrics, clarifying who owns each stage of the buyer journey, setting explicit decision-making and conflict-resolution protocols, and reviewing wins and losses together on a regular cadence.
The HBR data on this is unambiguous. The most-cited challenges in designing GTM strategy include ineffective coordination between teams (43%) and internal teams with misaligned or conflicting goals (42%). The top steps companies are taking to fix collaboration are clarifying roles and expectations (48%) and defining common metrics and KPIs (48%).
In a life science company, “internal teams” usually means four groups with four scorecards: sales chasing bookings, marketing chasing MQLs, application scientists protecting their time, and product management protecting the roadmap. The Bain partner in the report observes that no single function owns the customer journey end to end, so the handoffs are where deals leak -and that most companies skip the post-cycle conversation about what happened and what should change.
PSG’s Sales & Marketing Alignment process is built to fix exactly that. Unlike traditional training, it works on real issues in real time, and teams leave with what it takes to operate as a High-Performance Team (HPT):
Clear goals and agreement on business priorities
Commitment to winning for the business over self-interest
Defined protocols for decision-making
Personal and team ownership and accountability
An agreed-upon conflict resolution process
A depersonalized feedback methodology
Sales, marketing, and your application scientists pulling in different directions? PSG’s High-Performance Team alignment process gets commercial and technical teams onto shared goals, shared metrics, and clear ownership of the buyer journey. See Sales & Marketing Alignment Services →
What role does CRM play in closing the execution gap?
DIRECT ANSWERCRM is the operating system for GTM execution -it’s how coached behaviors and team agreements become visible and measurable -but the HBR data shows most companies own a CRM without getting a unified view of the buyer from it.
CRM is the most commonly used GTM tool in the survey, cited by 75% of respondents. Yet the number-one execution challenge is siloed data that doesn’t give a holistic view of buyer or account engagement (43%), and the number-one design challenge is systems that don’t integrate well (48%).
Coaching and alignment only compound when they’re wired into the system. When a scientist maps a buying group, it should live on the account record. When the HPT agrees on a shared definition of a qualified opportunity, it should be a lifecycle stage and a dashboard -not a slide. That’s why Bench to Business and HPT alignment work best alongside a CRM configured for how scientific buyers actually evaluate, validate, and buy.
Own a CRM but still can’t see the whole buying group? PSG Life Sciences is a HubSpot Gold partner that configures HubSpot around life science buying groups, sample and quote workflows, and shared sales-marketing dashboards. See HubSpot Life Sciences Pro →
Where should a life science CEO start?
DIRECT ANSWER: Start with a narrow pilot -one product line, one customer segment, one team -that combines scientist coaching, team alignment, and CRM visibility, prove the revenue impact, then scale it.
The HBR report recommends piloting new execution models before rolling them out, and an Adobe executive in the report advises picking a very specific slice -a single product set, customer segment, and geography -getting it right, and then expanding. That matches what works in life sciences:
Pick the slice. One product family and one buyer segment where your scientists are already in front of customers.
Coach the people. Put the customer-facing scientists through Bench to Business on those live accounts.
Align the team. Run the HPT process with sales, marketing, and technical support so everyone agrees on goals, stage ownership, and metrics.
Instrument the CRM. Make buying groups, stage definitions, and follow-up speed visible in HubSpot.
Review the cycle. Hold a joint win/loss review at 90 days -the conversation most companies skip -then scale what worked.
The companies that win aren’t the ones with the best GTM slide. They’re the ones whose scientists, marketers, and sellers execute the same plan, on the same data, toward the same number.
About the Author
Stephen Manobianco is Founder and Managing Director of PSG Life Sciences, a Princeton, NJ–based fractional commercialization firm and HubSpot Gold partner serving biotech, CRO/CDMO, life science tools, reagent, and diagnostics companies. As VP of Global Sales and Business Development at GENEWIZ, he helped scale revenue from $17M to over $100M. Over 25+ years he has coached several hundred scientists into customer-facing roles, and he leads PSG’s Bench to Business coaching program.
Is your scientific team ready for the commercial world? Talk to Steve about a commercial readiness assessment covering your customer-facing scientists, team alignment, and CRM execution. Contact PSG Life Sciences →
Quick-Reference FAQ
What does the HBR research say about B2B go-to-market execution?
The HBR research finds that 83% of B2B organizations call their go-to-market strategy very important, but only 38% describe it as very effective and only 32% say their sales, marketing, and other teams are very aligned in executing it.
Why does the strategy-to-execution gap hit life science companies harder?
Life science companies feel the execution gap more because their customer-facing roles are usually filled by PhD scientists and technical specialists who were hired for scientific depth, not commercial skill, and because they sell to buying groups of PIs, lab managers, core directors, and procurement that each weigh different criteria.
What separates go-to-market “leaders” from “laggards” in the HBR data?
GTM leaders in the HBR research are distinguished less by strategy than by execution discipline -they are far more aligned across teams, more likely to train their sales people, more likely to share common metrics, and far more likely to understand how their buyers actually buy.
How do you prepare PhD scientists to execute a go-to-market strategy?
Prepare PhD scientists for commercial roles with structured, life-science-specific coaching applied to their live accounts -covering discovery, buying-group mapping, account planning, and CRM discipline -with their manager involved so the new behaviors stick.
How do sales, marketing, and technical teams become a high-performance team?
Sales, marketing, and technical teams become a high-performance team by agreeing on shared goals and metrics, clarifying who owns each stage of the buyer journey, setting explicit decision-making and conflict-resolution protocols, and reviewing wins and losses together on a regular cadence.
What role does CRM play in closing the execution gap?
CRM is the operating system for GTM execution -it’s how coached behaviors and team agreements become visible and measurable -but the HBR data shows most companies own a CRM without getting a unified view of the buyer from it.
Where should a life science CEO start?
Start with a narrow pilot -one product line, one customer segment, one team -that combines scientist coaching, team alignment, and CRM visibility, prove the revenue impact, then scale it.
Source: Harvard Business Review Analytic Services, Aligning Go-to-Market Execution with Strategy to Better Address Complex Buyer Journeys (research report sponsored by LeanData; survey of 522 B2B decision-makers, September 2025).
High-Performance Science Teams™ helps diagnostics companies that sell both research-use-only (RUO) and clinical in vitro diagnostic (IVD) products run development as one team, assay development, R&D, regulatory, quality, clinical affairs, operations, medical affairs, and commercial. It targets the behaviors behind RUO data that can’t support an IVD submission, late regulatory strategy, design freezes that never hold, and commercial teams caught between two rulebooks.
Why do diagnostics companies struggle to move from RUO to clinical products?
Most diagnostics companies start the same way: a strong assay, launched as research use only, sold to translational labs and pharma partners. Revenue and publications build. Then the company decides to go clinical, a 510(k), De Novo, or PMA in the U.S., a CE-IVD under the EU IVDR, or a companion diagnostic tied to a pharma partner’s drug program.
That is where two operating models collide. RUO development rewards speed and iteration. Clinical development runs on design controls, verification and validation plans, a design history file, and quality system discipline. The same scientists, the same leadership team, and often the same commercial organization now have to work under both rulebooks at once.
Why is the regulatory environment raising the stakes for diagnostics teams?
Three shifts put more weight on how well diagnostics teams work across functions:
FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026, aligning 21 CFR Part 820 with ISO 13485:2016. Quality is now expected to operate as a management system across the company, not a department.
The EU IVDR transition was extended by Regulation (EU) 2024/1860, with legacy-device deadlines running to December 2027 for class D, December 2028 for class C, and December 2029 for class B and sterile class A devices — a long runway that is easy to under-staff.
The U.S. laboratory-developed test landscape shifted when a federal court vacated FDA’s LDT final rule in March 2025 and FDA rescinded it in September 2025, changing the calculus for companies that support LDT customers alongside their own kitted products.
What does team dysfunction look like inside a diagnostics company?
RUO data that can’t be reused. Assays developed without design-control habits produce analytical data that has to be regenerated for the IVD submission.
Regulatory strategy decided late. Intended use, claims, and the regulatory pathway are settled after the assay is locked, so clinical validation is designed around a moving target.
Design freeze that doesn’t hold. Assay development keeps optimizing sensitivity or specificity after verification planning starts, resetting V&V timelines.
Two cultures under one roof. The tools-and-RUO side and the regulated clinical side use different vocabularies, cadences, and definitions of done — and blame each other for delays.
Commercial caught between rulebooks. Sales teams face pressure to position RUO products with clinical labs, creating promotional risk and friction with regulatory and medical affairs.
Companion diagnostic timelines out of sync. The pharma partner’s clinical milestones move; the CDx team hears late and compresses analytical validation or clinical bridging to catch up.
Why don’t new eQMS software, regulatory consultants, or a reorganization fix it?
Diagnostics companies reach for vertical fixes: an eQMS platform for QMSR, a regulatory consultancy for the submission, a new Head of Quality, a split into separate research and clinical business units. Each can be the right call. None changes how assay development, regulatory, quality, and commercial decide together — and splitting the organization often just moves the seam.
The failure pattern is horizontal: decisions that belong to several functions but are owned by none. It needs a horizontal fix.
How does High-Performance Science Teams™ work for diagnostics teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to diagnostics leadership teams and core product teams, working on live programs, live submissions, and live partner commitments.
Program-risk pattern
Root behavior
What HPT installs
RUO data not usable for IVD
Regulatory and quality brought in after development
Regulatory, quality, and clinical affairs seated in the core team from feasibility onward
Late intended-use and pathway decisions
No clear owner for cross-functional calls
A decision charter naming who decides intended use, claims, and pathway — and by when
Design freeze that slips
No agreed rule for “good enough”
A freeze protocol tied to target performance specifications, with a named decision owner
RUO vs. clinical culture clash
Different goals and definitions of done
Shared program goals and working norms that span both sides of the business
Commercial–regulatory friction
Disagreement handled by escalation
A conflict protocol that settles positioning and claims questions in the room
CDx timeline surprises
Partner milestones held by one person
Cross-functional partner team with early-warning norms and shared accountability
What is outside the scope of the program?
High-Performance Science Teams™ is not regulatory consulting, clinical study design, or reimbursement strategy. It works alongside your regulatory advisors and quality systems, making the team that uses them faster and more aligned.
How does this connect to the commercial team?
Bench to Business™, our companion program, coaches the field application scientists, clinical account managers, and pharma partnership leads who carry diagnostics to customers — including how to communicate data accurately across RUO and clinical audiences. Many diagnostics companies run both programs as they move into regulated markets.
Who is it for?
CEOs, CTOs and CSOs, and VPs of R&D, Assay Development, Regulatory Affairs, Quality, Clinical Affairs, Medical Affairs, and Commercial at molecular, NGS, immunoassay, and digital pathology diagnostics companies — especially those converting RUO products to IVD, preparing for QMSR or IVDR milestones, or developing companion diagnostics with pharma partners.
How do we get started?
Start with the Science Team 360™ — a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your diagnostics team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
What is the difference between an RUO and an IVD product?
A research-use-only (RUO) product is labeled for research and may not be used for clinical diagnostic purposes. An in vitro diagnostic (IVD) product is intended for clinical use and must meet regulatory requirements such as FDA clearance or approval, or CE marking under the EU IVDR, including design controls and quality system compliance.
Why do RUO-to-IVD transitions take longer than planned?
Common causes are team-level: RUO development done without design-control discipline, intended use and regulatory pathway decided late, design freezes that slip, and gaps between assay development, regulatory, quality, and commercial.
When did FDA’s QMSR take effect?
FDA’s Quality Management System Regulation, which aligns 21 CFR Part 820 with ISO 13485:2016, took effect on February 2, 2026.
Does High-Performance Science Teams™ replace regulatory consultants?
No. It is not regulatory consulting. It improves how your internal team decides, shares information, and holds itself accountable while working with regulatory and quality advisors.
How do we start?
With the Science Team 360™, a confidential diagnostic that shows where alignment, decision rights, and accountability break down across your R&D, regulatory, quality, and commercial teams.
Sources
U.S. FDA, “Quality Management System Regulation (QMSR)” — https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
The FDA Law Blog, “Federal District Court Vacates FDA’s Laboratory Developed Tests Final Rule,” April 2025 — https://www.thefdalawblog.com/2025/04/federal-district-court-vacates-fdas-laboratory-developed-tests-final-rule/
AHA News, “FDA vacates final rule regulating lab-developed tests as medical devices,” September 18, 2025 — https://www.aha.org/news/headline/2025-09-18-fda-vacates-final-rule-regulating-lab-developed-tests-medical-devices
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
High-Performance Science Teams™ helps service CROs , study directors, project managers, laboratory teams, QA, report writing, and business development, operate as one team from quote to final report. It targets the behaviors that cost repeat business: timelines sold before operations validates them, late bad news, unmanaged scope change, and sponsors hearing different answers from different people.
Why do sponsors leave CROs whose science is good?
Sponsors rarely switch CROs because the data was wrong. They switch because the experience was: a study start that slipped after the contract was signed, a report that arrived three weeks late with no warning, a scope change that became a billing dispute, a study director who was the only person who knew what was happening.
Every one of those is a team failure dressed up as an individual one. In a services business, the sponsor experiences the seams between your functions as your brand.
What does team dysfunction look like inside a service CRO?
BD sells a timeline operations didn’t validate. The quote goes out on a study-start date the lab schedule can’t support, and the study director inherits the credibility problem.
The study director as single point of failure. Scientific, client, and operational decisions all route through one person, who becomes the bottleneck.
Blurred study director and project manager roles. Sponsors don’t know who owns the timeline versus the science, and neither do the teams.
Scope creep absorbed instead of managed. Added endpoints, extra timepoints, and protocol changes get done without change orders, margin leaks and resentment builds.
Late bad news. A failed run, a QA audit finding, or an animal-availability issue waits until it can’t be hidden.
Report turnaround drift. The handoff from in-life or bench teams to report writing and QA review has no shared deadline owner.
What does team science say about fixing it?
Two of the most cited findings on team effectiveness apply directly. Gallup’s research on managers found they account for at least 70% of the variance in team engagement across business units. And Google’s Project Aristotle found psychological safety whether team members feel safe to take risks and raise problems to be the most important factor distinguishing effective teams.
Neither was studied in CROs specifically. But both describe exactly the conditions under which bad news travels early and scope changes get raised instead of absorbed.
How does High-Performance Science Teams™ work for CRO teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to CRO site leadership and study teams, working on live sponsor programs.
Client-risk pattern
Root behavior
What HPT installs
Timelines sold that ops can’t hit
BD and operations goals misaligned
A quote-to-study-start protocol with operations sign-off before commitment
Study director bottleneck
Hub-and-spoke decision-making
Explicit decision rights across study director, PM, and lab leads
Unmanaged scope change
Avoidance of difficult sponsor conversations
Shared norms and scripts for raising scope and change orders early
Late bad news
Low psychological safety
An early-warning protocol: raise risk within a set window, no blame
Report turnaround drift
No shared owner across handoffs
Peer accountability for report milestones across lab, writing, and QA
How does this connect to the customer-facing side of the CRO?
High-Performance Science Teams™ aligns the team behind the study. Bench to Business™, our companion program, builds the customer-facing skills of study directors, scientific project managers, and BD scientists, discovery conversations, sponsor updates, and handling objections. CROs that run both close the gap between what is sold and what is delivered.
Who is it for?
Presidents and general managers, VPs of Operations, heads of study direction and project management, and BD leaders at discovery, safety assessment, DMPK, bioanalytical, and specialty service CROs — especially organizations growing site headcount or consolidating after acquisition.
How do we get started?
Start with the Science Team 360™, a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your CRO site or study team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
Why do sponsors switch CROs?
Sponsors commonly switch because of the service experience rather than the science: missed study-start dates, late or surprising updates, unmanaged scope changes, and inconsistent communication across the CRO team.
How can a CRO improve client retention?
By aligning BD, study direction, project management, lab operations, and QA on shared commitments to each sponsor, validating timelines before quoting, raising risks early, and managing scope changes openly.
What is the difference between a study director and a project manager in a CRO?
Roles vary, but typically the study director owns scientific conduct and GLP compliance of the study, while the project manager owns timeline, budget, and sponsor logistics. High-performing teams make these decision rights explicit.
Does High-Performance Science Teams™ replace project management tools or GLP processes?
No. It improves how the team works within them, how it decides, escalates, and holds itself accountable.
How do we start?
With the Science Team 360™, a confidential diagnostic that shows where your study teams’ alignment, decision rights, and accountability break down.
Sources
Gallup, State of the American Manager: Analytics and Advice for Leaders (2015) — https://www.gallup.com/services/182138/state-american-manager.aspx
Google re:Work, “Guide: Understand team effectiveness” (Project Aristotle) — https://rework.withgoogle.com/guides/understanding-team-effectiveness/
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
High-Performance Science Teams™ helps clinical CROs run each study as one team: project management, clinical monitoring, site start-up, data management, biostatistics, medical monitoring, and BD. It targets the behaviors that erode sponsor trust after award: timelines promised in the bid defense that delivery never validated, risk reported late, change orders that become disputes, and sponsors hearing different stories from different functions.
Why do sponsors lose confidence in a clinical CRO?
The bid defense goes well. The team in the room is sharp, the enrollment plan is credible, the start-up timeline is aggressive but defensible. Six months later, site activation is behind, the sponsor’s clinical lead is escalating to your executive sponsor, and the joint operating committee has become a weekly status interrogation.
The science of running the trial rarely fails. What fails is the team behind it: the handoff from proposal to delivery, the way risk moves from a CRA’s visit report to the sponsor’s inbox, and whether project management, monitoring, data management, and biostatistics give the sponsor one answer or four.
What does a slipped day cost your sponsor?
Your sponsors know the number. Tufts Center for the Study of Drug Development puts the mean direct cost of running a Phase II or III trial at roughly $40,000 per day, about $23,700 for Phase II and $55,700 for Phase III (Tufts CSDD, 2024). Every day a CRO team loses to an internal handoff is a day the sponsor pays for.
Protocol amendments magnify it, and the CRO executes most of them. Tufts CSDD’s latest benchmark 950 protocols from 16 pharma companies and CROs, published in 2024 found 76% of protocols now have at least one amendment, averaging 3.3 each. Implementing one takes an average of 260 days from identifying the need to final oversight approval, and investigative sites operate on different protocol versions for an average of 215 days. Most amendments are now judged unavoidable. How fast and cleanly the CRO team implements them is not.
What does team dysfunction look like inside a clinical CRO?
The bid-to-delivery gap. Proposals and BD commit to a site activation curve and enrollment plan the delivery team never pressure-tested, and the project manager inherits a timeline to rebaseline in month three.
Green until it’s red. Risk sits in CRA visit reports, site feasibility notes, and query aging reports long before it reaches the sponsor, because no one wants to be the function that raised it.
The project manager as switchboard. Every decision routes through the PM, who has accountability for the study but no authority over monitoring, data management, or biostatistics resources.
Change orders as conflict. Out-of-scope work is absorbed to keep the sponsor happy, then surfaces months later as a change order the sponsor sees as a surprise.
Amendment rollout without an owner. Regulatory, start-up, monitoring, and data management each implement their piece of an amendment on their own clock, and sites run mixed protocol versions longer than they should.
Four voices to the sponsor. The PM, the clinical team lead, the data manager, and the medical monitor each describe study status differently in the same governance meeting.
Why don’t new CTMS platforms, reorganizations, or more PMs fix it?
Clinical CROs reach for vertical fixes when delivery slips: a new CTMS or risk-based monitoring platform, a shift between full-service and functional service models, a regional reorganization, more project managers. The dashboard gets better. The handoffs don’t.
Adding project managers to a team without clear decision rights adds switchboards, not speed. And sponsors who switch CROs discover that the new provider’s delivery team has the same habits. The problem is horizontal how functions work together on one study and it needs a horizontal fix.
How does High-Performance Science Teams™ work for clinical CRO teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to CRO delivery leadership and cross-functional study teams, working on live studies and live sponsor relationships. Where it helps, sponsor counterparts can be included so governance runs as one team.
Sponsor-trust pattern
Root behavior
What HPT installs
Timelines rebaselined after award
BD and delivery goals misaligned
A bid-to-delivery protocol: delivery leads validate start-up and enrollment assumptions before the bid defense
Risk reported late
Low candor across functions
An early-warning protocol: study risks raised within a set window, without blame
PM bottleneck
Accountability without authority
Explicit decision rights across PM, clinical team lead, data management, and biostatistics
Change-order disputes
Avoiding hard sponsor conversations
Shared norms for flagging scope change at the moment it occurs
Slow amendment rollout
No cross-functional owner
Peer accountability for amendment implementation across regulatory, start-up, monitoring, and data management
Mixed messages in governance
No single internal position
An align-before-you-speak rule so the sponsor hears one study status
How does this connect to the CRO’s customer-facing roles?
High-Performance Science Teams™ aligns the delivery team. Bench to Business™, our companion program, coaches the people who carry the sponsor relationship — project managers, clinical team leads, CRAs moving into lead roles, and BD scientists to communicate data, negotiate scope, and deliver difficult news with confidence. CROs that run both close the gap between what the bid defense promised and what the study delivers.
What is outside the scope of the program?
High-Performance Science Teams™ doesn’t replace feasibility analytics, patient-recruitment vendors, or your quality management system. It makes the team that uses them faster, more candid, and more consistent with the sponsor.
Who is it for?
CRO presidents and COOs, VPs of Clinical Operations and Project Delivery, project directors, heads of BD and proposals, and CHROs at full-service, specialty, and therapeutic-area-focused clinical CROs — especially those scaling delivery teams, integrating acquisitions, or working to become a preferred provider for key sponsors.
How do we get started?
Start with the Science Team 360™ — a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your CRO delivery team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
Why do sponsors switch clinical CROs?
Sponsors most often lose confidence over delivery experience rather than scientific capability: timelines rebaselined soon after award, risks reported late, change orders that arrive as surprises, and inconsistent status reporting across the CRO team.
How long does a protocol amendment take to implement?
According to Tufts CSDD’s 2024 benchmark of 950 protocols, the average time from identifying the need to amend to last oversight approval is 260 days, and sites operate on different protocol versions for an average of 215 days.
How can a clinical CRO improve the sponsor relationship?
By aligning BD, project management, monitoring, data management, and biostatistics on shared commitments to each study — validating timelines before the bid defense, raising risk early, flagging scope changes when they occur, and presenting one study status to the sponsor.
Does High-Performance Science Teams™ replace CTMS or risk-based monitoring?
No. CTMS and risk-based monitoring surface risk and status. High-Performance Science Teams™ improves how the CRO team acts on that information and communicates it to the sponsor.
How do we start?
With the Science Team 360™, a confidential diagnostic that shows where alignment, decision rights, and accountability break down in your study delivery teams.
Sources
Tufts CSDD, “How Much Does a Day of Delay in a Clinical Trial Really Cost?” White paper, August 2024 — https://csdd.tufts.edu/publications/articles
Getz K., Smith Z., Botto E., Murphy E., Dauchy A. “New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance.” Therapeutic Innovation & Regulatory Science 58:539–548 (2024) — https://doi.org/10.1007/s43441-024-00622-9
Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.
A recruiting profile from Corning Life Sciences is, read the right way, one of the clearest public illustrations of why technical hires stall in customer-facing roles and what it actually takes to fix it.
Corning Life Sciences recently published a profile of Sascha Kiesslich, a field application scientist (FAS) on their team, alongside the account manager he partners with, Chris Sheen. On its surface, it’s a career story aimed at scientists weighing a move out of academia. But if you run a commercial organization that sells to researchers, read it again. It is one of the clearest public descriptions of the exact gap we built Bench to Business™ to close.
The credential opens the door. It doesn’t close the deal.
Kiesslich holds a PhD in biomedical engineering, and Corning is explicit that his technical depth is what lets him understand what customers actually need. That is the part most companies already believe: hire the scientist, get the credibility. And it is true, deep expertise is what earns a researcher’s attention and opens the conversation.
But the profile is just as clear that the credential is the entry ticket, not the job itself.
The job is customer-facing, full stop.
Read what the role actually involves in Corning’s telling: acting as an information hub alongside the account manager, delivering scientific seminars and product demonstrations, presenting at conferences, and troubleshooting both on-site and remotely at customer facilities. Corning even frames the scientist-and-account-manager pairing as a “dynamic duo” that looks after the whole customer relationship.
Strip away the lab coat, and that is a commercial motion: discovery, presentation, team selling, and account management. The science gets you into the room. What happens in the room is a different skill set entirely.
Trust is the currency, and it is learned.
The account manager in the story is blunt about what makes the partnership work: communication, the ability to speak the customer’s language, and above all trust. He describes every business relationship as built on trust, and explains that a scientist sharing genuine expertise is precisely what earns it.
Notice what that is, and what it is not. It is not the PhD. It is the ability to translate expertise into a relationship, to be credible and consultative at the same time. That is coachable. It is also, for most scientists new to a commercial role, almost entirely unpracticed.
The quiet tell: Corning trained him.
Here is the line commercial leaders should not skim past. Kiesslich describes receiving substantial onboarding to prepare for the role, including direction on how to integrate business with science, and the chance to rehearse presentations internally and get feedback before he was ever in front of a customer.
In other words: even at a company with Corning’s resources, customer-facing competence did not arrive by osmosis with the diploma. It was deliberately built. Corning has a world-class internal enablement engine to do that building.
Most companies selling into pharma, biotech, academic, and government research don’t have that engine. In the $10M–$500M-revenue tools, CRO/CDMO, and diagnostics segment, the usual pattern is: hire the PhD for credibility, hand them a territory, and hope commercial fluency develops on the job. Sometimes it does. Often it costs 6–12 months of ramp, a thinner pipeline than the headcount promised, and, worst case, the loss of an expensive, hard-to-replace technical hire who was never given a path to competence.
The lesson for commercial leaders
The Corning story is a validation, not a contradiction. It shows a scientist thriving in a customer-facing role precisely because someone invested in building the commercial half of the job. And the competencies involved are nameable and teachable:
Commercial identity & executive presence
Territory & account strategy
Discovery & consultative selling
Value communication & presentation
Stakeholder management & team selling
Objection handling & negotiation
CRM & pipeline discipline
Those are the seven domains we measure and coach in Bench to Business™. None of them ask the scientist to stop being a credible scientist. All of them are the difference between a PhD who can explain a product and a professional who can move a customer.
Start with a diagnosis, not a curriculum
If Corning’s story resonates, if you’ve hired brilliant scientists into customer-facing roles and watched some of them ramp slowly or retreat to the technical comfort zone, the first step isn’t a training program. It’s a diagnosis.
The Commercial Readiness 360™ baselines your team across all seven domains before you spend a dollar closing the gap. Lead with the diagnostic. What it surfaces is almost always more specific, and more fixable, than “they need sales training.”
See the gap before you close it. Request the free Commercial Readiness 360™ • bench2business.bio • steve@bench2business.bio
Source: Corning Life Sciences, “Exploring the Role of a Field Application Scientist,” corning.com. Role details and characterizations are paraphrased with attribution; the phrase “dynamic duo” is quoted directly. Quotations and specifics are drawn from Corning’s profile of Sascha Kiesslich, Ph.D., and account manager Chris Sheen.
